Controlling for all covariates, APP was associated with increased hyperprolactinaemia (adjusted odds ratio 2.46; 95% CI 1.87–3.24) within the period of APP prescribing and up to 30 days after as compared to antipsychotic monotherapy. Here, APP is linked to hyperprolactinemia.